Kidney Cancer Clinical Trial

Pencil Beam Scanning in Patients With Renal Tumors

Summary

This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.

View Full Description

Full Description

Patients with renal tumors including Wilms and clear cell sarcoma of the kidney (CCSK) are treated with multimodality therapy which may include surgery, chemotherapy, and radiation. While long-term disease control is excellent, these patients remain at risk for early and late toxicities partially from radiation. There have been no significant changes to traditional photon radiation fields, which encompass the post-operative bed, anterior abdomen, and vertebral body. Proton beam radiation using pencil beam scanning, which is characterized by Bragg peak dose deposition and high conformality of dose to target regions, is ideally suited to treat the retroperitoneum. This pilot study evaluates pencil beam scanning proton therapy (PBS-PT) to:

result in low acute gastrointestinal toxicity in patients receiving radiation therapy for renal tumors as measured by laboratory evaluations, clinician-assessed, and patient reported health related quality of life outcomes
decrease the duration of radiation therapy
compare doses to organs at risk (OARs) using PBS-PT as compared to traditional photon fields

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Less than 30 years of age

Diagnosis

a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including

Any patient with favorable histology (FH), stage III disease
Any patient with focal or diffuse anaplasia
Any patient with CCSK
The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK

Exclusion Criteria:

Prior radiotherapy to the region of the study cancer
Chemotherapy administered for diagnosis of Wilms tumor or CCSK
Pregnant or breastfeeding

Study is for people with:

Kidney Cancer

Phase:

Early Phase 1

Estimated Enrollment:

28

Study ID:

NCT03810651

Recruitment Status:

Recruiting

Sponsor:

Children's Hospital of Philadelphia

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Children's Hospital of Philadelphia
Philadelphia Pennsylvania, 19104, United States More Info
Christine Hill-Kayser, MD
Contact
215-590-2810
[email protected]
Ratnakar Patti
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Early Phase 1

Estimated Enrollment:

28

Study ID:

NCT03810651

Recruitment Status:

Recruiting

Sponsor:


Children's Hospital of Philadelphia

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.